A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...